Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Marnix Wieffer
Drug Safety Information Specialist
About the author:
As drug safety information specialist, I support pharmaceutical companies in identifying potential drug toxicity concerns and adverse effects. During my first 3 years at Elsevier, I have been working with both academic and corporate customers in northern Europe. As senior marketing manager, I am currently responsible for Elsevier’s drug safety messaging, internal training and market engagement.
Posts by Marnix Wieffer
Making better drug development decisions with extracted preclinical and clinical data
Posted on June 12th, 2019 in Pharma R&D
Improving the speed and ease of collecting pharmacovigilance data
Posted on June 12th, 2019 in Pharma R&D
Learn how the staff of biotechnology company 4P-Pharma uses Elsevier’s Embase to address challenges in conducting clinical trials.
(more…)The Role of Data in Propelling Clinical Trial Progress
Posted on April 1st, 2019 in Pharma R&D
It’s a well known fact that the majority of drugs in development never make it to market despite the immense amount of time, money and effort. The application of data and analytics solutions to the R&D process as early as possible has proven to be a pivotal strategy to help improve trial design.
(more…)How Big Data Transforms Reactive Drug Safety to Proactive Pharmacovigilance
Posted on March 7th, 2019 in Pharma R&D
Adverse drug reactions can be costly and cost is just the tip of the iceberg. This is highlighted by an FDA website which cites troubling statistics such as the 100k deaths and over 2 million serious adverse drug reactions experienced each year…
(more…)
